Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans
- 63 Downloads
A dose of 1,000 mg probenecid was administered orally to 14 human volunteers in order to quantify the maximal rate of formation and excretion of probenecid acyl glucuronide in the urine. Probenecid showed dose-dependent pharmacokinetics. Plasma protein binding of probenecid was high, being somewhat higher in males (90.7±1.4%) than in females (87.9±1.4%; p=0.0019). It was shown that probenecid is metabolized by cytochrome P-450 into at least two phase I metabolites. Each of the metabolites accounted for less than 12% of the dose administered; the main metabolite probenecid acyl glucuronide, representing 42.9±13.2% of the dose, was only present in urine and not in plasma. The renal excretion rate-time profile of probenecid acyl glucuronide showed a plateau value in the presence of an acidic urine pH. This plateau value was maintained for about 10 h at the dose of 1,000 mg. The height of the plateau value depended on the individual and varied between 250 and 800μg/min (15–50 mg/h). It was inferred that probenecid acyl glucuronide is formed in the kidney during blood-to-lumen passage through the tubular cells. We conclude that the plateau value in the renal excretion rate of probenecid glucuronide reflects itsVmax of formation.
KeywordsClearance, renal Glucuronates Metabolism Pharmacokinetics Probenecid Protein binding
Unable to display preview. Download preview PDF.
- 1.Beyer KH. New concept of competitive inhibition of the renal tubular excretion of penicillin. Science 1947;105:94–5.Google Scholar
- 2.Beyer KH. Functional characteristics of renal transport mechanisms. Pharmacol Rev 1950;2:227–80.Google Scholar
- 4.Beyer KH. Factors basic to the development of useful inhibitors of renal transport mechanisms. Arch Int Pharmacodyn 1954;48:97–117.Google Scholar
- 9.Cunningham RF, Israeli ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokin 1981;13(5): 135–51.Google Scholar
- 14.Perel JM, Dayton PG, Yü TF, Gutman AB. Studies of the renal excretion of probenecid acyl glucuronidation in man. Eur J Clin Pharmacol 1971;3:106–12.Google Scholar
- 20.Vree TB, Beneken Kolmer EWJ. Direct measurement of probenecid and its glucuronide conjugate by means of high performance liquid chromatography in plasma and urine of humans. Pharm Weekbl [Sci] 1992;14(3):83–7.Google Scholar
- 21.Vree TB, Beneken Kolmer EWJ, Wuis EW, Hekster YA. Capacity-limited renal glucuronidation of probenecid by humans. A pilotV max-finding study. Pharm Weekbl [Sci] 1992;14(5):325–31.Google Scholar
- 22.Jaffé M. Untersuchungen über die Entstehung des Kreatins im Organismus. Hoppe Seylers Z Physiol Chem 1906;48:430–68.Google Scholar
- 24.SAS user's guide. Basics 1982 edition. Cary: SAS Institute, 1982.Google Scholar
- 25.Vree TB, Van den Biggelaar-Martea M, Verwey-van Wissen CPWGM. Determination of naproxen and its metabolite O-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatography. J Chromatogr Biomed Appl 1992;578:239–49.Google Scholar